Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCVAC/OvCa

Drug Profile

DCVAC/OvCa

Alternative Names: Dendritic cell vaccine/Ovarian cancer - Sotio

Latest Information Update: 03 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SOTIO
  • Developer Peking University; SOTIO
  • Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 31 Aug 2021 SOTIO withdraws the phase III VITALIA trial in Fallopian tube cancer, Peritoneal cancer and relapsed Ovarian cancer (Late-stage disease)
  • 04 Jun 2021 Updated efficacy and safety data from the phase II SOV01 trial in Ovarian cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 23 Mar 2021 Phase-II clinical trials in Fallopian tube cancer (First-line therapy, Late-stage disease, Adjuvant therapy) in China (SC) (NCT04834544)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top